Key result
The optimal timing of ticagrelor pretreatment in NSTE-ACS remains inadequately studied, while early invasive intervention (<24 h) shows a mortality benefit in selected high-risk patients.
Why the study?
The optimal timing of ticagrelor pretreatment has not been adequately studied in patients with NSTE-ACS.
Early invasive intervention (<24 h) provides a mortality benefit in selected high-risk patients with NSTE-ACS.
Optimal P2Y12 timing in NSTE-ACS remains uncertain; leaves open questions on pretreatment benefits versus bleeding in contemporary invasive strategies.
In the current era, the antithrombotic treatment of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) includes standard aspirin, and one of the potent P2Y12 inhibitors ticagrelor or prasugrel. The optimal timing of ticagrelor has not been adequately studied, while prasugrel is only recommended after coronary angiography prior to PCI. The invasive strategy, including indication and timing of angiography, depends on risk stratification and a mortality benefit has been shown in selected high-risk NSTE-ACS undergoing early (<24 h) intervention.
No takes yet. Share an insight, caveat, or question.
Camaro et al. (2020) conducted a review in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS). Antithrombotic pretreatment and invasive strategies was evaluated. The optimal timing of ticagrelor pretreatment in NSTE-ACS remains inadequately studied, while early invasive intervention (<24 h) shows a mortality benefit in selected high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: